PAPAP for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
PAPAP may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed pAPAP in detail.
, In Silico #Favipiravir Isostere a Promising Remedy: Lead discovery for Covid-19 remedy. Laila A Abou-Zeid; Associate Professor. FOP, Delta University & Mansoura University, Center for Open Science, doi:10.31219/osf.io/myw67
<p>A newly emerged Human Coronavirus (HCoV) is reported three months ago in Wuhan, China (COVID-19). Based on the World Health Organization (WHO) reports until today more than 4000 deaths from the 114,000 confirmed cases reported. The current study aims to shed light on one of the promising lead against COVID-19.P-Amino-Antineoplastone small molecule that therapeutically evaluated as anticancer is evaluated for its complementarity and recognition at the binding site of the NSP15 endoribonuclease protein that just issued at 3rd of March 2020; at the protein data bank coded 6VWW.Based on the presence of common structural features in both pAPAP and the antiviral drug (Favilavir) that announced as the first line for treatment of positively tested coronavirus patients in China. In silico molecular docking of p-amino-phenylacetyl pipredinedione (pAPAP) in complex with NSP15 showed promising binding affinity that gives great anticipation inhibiting the endoribonuclease COVID19.</p>